On Wednesday, Metsera got a positive adjustment to its Relative Strength (RS) Rating, from 88 to 93.
Here Are 3 Keys For Successful Stock Investing
This unique rating tracks technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks matches up against the rest of the market.
Over 100 years of market history reveals that the market's biggest winners typically have an RS Rating of above 80 as they launch their largest price moves.
Metsera is not currently offering a proper buying opportunity. See if the stock goes on to build a sound pattern that could kick off a new price move.
Metsera reported 0% EPS growth in its most recent report, while sales growth came in at 0%.
The company earns the No. 200 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Anbio Biotechnology and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
